Revenue by source
LabCorp Diagnostics$10.88BCovance Drug Development$0.00Clinical diagnostics laboratory$0.00Routine Testing$0.00Genomic and Esoteric Testing$0.00Ontario, Canada$0.00Other Segments$0.00
| Segment | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| LabCorp Diagnostics | - | $5.47B | - | $6.20B | $6.59B | $14.34B | $6.66B | $6.66B | $10.36B | $9.20B | $9.42B | $10.14B | $10.88B |
| Covance Drug Development | - | $343.10M | - | - | $2.84B | $6.07B | $2.19B | $2.34B | $5.85B | $5.71B | $2.77B | - | - |
| Clinical diagnostics laboratory | - | - | $5.68B | $6.20B | $6.59B | - | - | - | - | - | - | - | - |
| Routine Testing | $3.25B | - | - | - | - | - | - | - | - | - | - | - | - |
| Genomic and Esoteric Testing | $2.09B | - | - | - | - | - | - | - | - | - | - | - | - |
| Ontario, Canada | $335.00M | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Segments | - | - | $329.40M | - | - | - | - | - | - | - | - | - | - |
Revenue by country
North America$13.09BUNITED STATES$0.00Other countries$976.40MEurope$2.05BSWITZERLAND$0.00CANADA$0.00Ontario, Canada$0.00UNITED KINGDOM$0.00
| Segment | 2012 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|
| North America | - | - | - | - | - | - | $11.53B | $13.09B |
| UNITED STATES | - | - | - | $8.23B | - | - | - | - |
| Other countries | - | - | - | $857.70M | $1.18B | $1.20B | $941.00M | $976.40M |
| Europe | - | - | - | - | - | - | $1.51B | $2.05B |
| SWITZERLAND | - | $359.70M | $450.50M | $484.40M | - | - | - | - |
| CANADA | - | $290.40M | $295.80M | $327.80M | - | - | - | - |
| Ontario, Canada | $335.00M | - | - | - | - | - | - | - |
| UNITED KINGDOM | - | - | - | $302.00M | - | - | - | - |